The Murdoch Children’s Research Institute, University of Melbourne, Monash University and The Northern Hospital are conducting a study testing intranasal heparin to treat early COVID-19 infection.
Heparin is a naturally occurring sugar molecule which has been used for over 80 years to treat a range of medical problems. Recent studies suggest it binds the COVID-19 virus and may reduce the virus’ ability to enter cells.
We believe heparin may be able to treat people with early COVID-19 infections and prevent infection amongst their close household contacts, helping to reduce the spread of the virus.
Who can be in this study?
- Any person aged over 5 years of age who tests positive to COVID-19 or is a household contact of someone of any age who tests positive to COVID-19.
- At least one other person in each household must consent to participate to be randomized.
Who is NOT eligible to be in this study?
- Children aged less than 5 years cannot be randomized to therapy but can contribute to outcomes.
- People with an allergy to heparin.
- People with heparin-induced thrombocytopenia (HIT).
- People with recurrent blood nose that has required hospitalization in the last 3 months.
Study flyer: INHERIT Study Flyer
Study contact email: INHERIT.Study@nh.org.au
Site Principal Investigator (PI): Professor Donald Campbell
Chief Investigator (CI): Professor Paul Monagle